Clinical and biomarker characteristics of Huntington’s Disease patients recently proposed for huntingtin-lowering clinical trial inclusion
Objective: We investigated plasma NfL levels, as well as clinical measures, in Huntingtin (Htt)-mutation carriers 48 years of age and under, with a CAP score…The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit
Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…Contemporary study of the difficulties of late diagnostics in patients with Huntington’s disease in Uzbekistan
Objective: To identify the causes that lead to late diagnosis of Huntington's disease. Background: Huntington's disease is a rare, progressive, and fatal autosomal dominant neurodegenerative…A randomized, sham-controlled, crossover trial on Transcranial pulsed current stimulation (tPCS) in Huntington disease
Objective: 1. To assess brain network level dysfunction of Huntington disease (HD). 2. To evaluate the effectiveness of 2-week home-based chronic non-invasive transcranial brain stimulation (NIBS) in…Safety and tolerability of Nilotinib in patients with Huntington’s disease
Objective: To investigate the safety and tolerability of nilotinib, an FDA-approved drug for leukemia, in individuals with Huntington’s disease (HD). Background: Previous clinical studies in…Perceptions of Palliative Care in Huntington’s Disease
Objective: This study aims to identify perceptions of palliative care in Huntington’s Disease (HD), palliative care needs of patients with HD, and at what point…An unusual cause of choreoathetosis: PRES and Goodpasture’s Syndrome
Objective: Our aim is to shed light on an usual cause of choreoathetosis in a medically complex case. Background: Goodpasture’s syndrome(GBS) is a rare autoimmune…Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease
Objective: To evaluate long-term deutetrabenazine safety on motor, psychiatric, and cognitive measures in participants with chorea associated with Huntington disease (HD). Background: Deutetrabenazine, a vesicular…Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 11
- Next Page »